Curis (CRIS) Cash from Financing Activities (2010 - 2026)
Curis (CRIS) reported Cash from Financing Activities of $18.9 million for Q1 2026, up 151.31% on a YoY basis from $7.5 million in Q1 2025, and up 16016.81% quarter-over-quarter from -$119000.0 in Q4 2025.
Curis (CRIS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Curis has reported Cash from Financing Activities for 17 years, with the latest figure at $18.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 151.31% year-over-year to $18.9 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (up 58.21% YoY), and the FY2025 full-year result was $9.8 million, up 184.11% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $18.9 million, up from -$119000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $18.9 million in Q1 2026, with the low at -$2.4 million in Q1 2024.
- Historically, Cash from Financing Activities has averaged $2.4 million across 5 years, with a median of -$852000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 587.66% — and 2024, when it sank 112.14%.
- Curis' Cash from Financing Activities stood at -$1.4 million in 2022, then slumped by 52.59% to -$2.1 million in 2023, then soared by 516.95% to $8.8 million in 2024, then slumped by 101.35% to -$119000.0 in 2025, then jumped by 16016.81% to $18.9 million in 2026.
- The last three Cash from Financing Activities figures came in at $18.9 million (Q1 2026), -$119000.0 (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Curis | 8.58 Mn | -6.42 Mn | - | 18.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.94 Mn |
| Mar 31, 2026 | 18.94 Mn |
| Dec 31, 2025 | -119,000.00 |
| Dec 31, 2025 | -119,000.00 |
| Sep 30, 2025 | 4.48 Mn |
| Sep 30, 2025 | 4.48 Mn |
| Jun 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -2.14 Mn |
| Mar 31, 2025 | 7.54 Mn |
| Mar 31, 2025 | 7.54 Mn |
| Dec 31, 2024 | 8.83 Mn |
| Dec 31, 2024 | 8.83 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | -1.46 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |